STAA · STAAR Surgical Company

Current Thesis

STAAR Surgical Company’s China-recovery re-rating thesis has failed its published price test; rebuilding the case requires stronger sales evidence and a weekly close above the former $23.50 shelf. The 2026-09-18 reference close of $20.82 breached the $22.00 weekly-close invalidation published on 2026-09-06. That is an observed failure, not an approaching risk.

The narrative is dead — the September 18 close extends the structural failure first identified at the 2026-08-21 weekly close of $23.14. This classification concerns the equity re-rating thesis, not the viability of the business. The proposed economic story remains that normalized China distributor orders and broader adoption of implantable lenses can sustain profitable growth; the August results establish a recovery quarter, not its durability.

There are developments beyond the September 6 note. STAAR announced David Bailey as chief commercial officer on 2026-09-08 and released its refractive-surgery market report on 2026-09-10. The subsequent September 18 close remained below the published invalidation level; these announcements do not establish a renewed market re-rating. STAAR announcements

Bullish and bearish views on STAAR Surgical Company

The model's bull view on STAAR Surgical Company (STAA), in brief: Profitability returned with China orders. The bear view: The published structure has broken. The adjusted September 18 close of $20.82 is below the $22.00 weekly-close condition retained from the September 6 research note. Lowering that threshold now would change the original test after failure. Growth remains geographically uneven.… Both cases follow in full.

Bull Case

• Profitability returned with China orders. The 2026-08-12 results reported second-quarter revenue of $93.5 million, up 111% year over year, and net income of $8.1 million. These are measured operating improvements supporting the recovery argument. Second-quarter results
• Liquidity supports the operating recovery. Cash, cash equivalents and available-for-sale investments totaled $181.5 million at 2026-07-03, according to the August 12 release. That balance does not establish a market-price floor. Quarterly financial summary
• Consumer research supports an adoption hypothesis. STAAR’s 2026-09-10 report drew on 7,800 respondents, with fieldwork conducted between March 2025 and May 2026. The company reported that 58% favored a reversible option; this measures stated preferences, not subsequent procedures or revenue. Company report announcement

Bear Case

• The published structure has broken. The adjusted September 18 close of $20.82 is below the $22.00 weekly-close condition retained from the September 6 research note. Lowering that threshold now would change the original test after failure.
• Growth remains geographically uneven. The 2026-08-12 release reported China revenue of $52.3 million, up more than 100% year over year, against ex-China revenue of $41.2 million, up 6.0%. Europe, the Middle East and Africa declined 1%. Second-quarter results
• A new analyst revision weakened. Argus’s 2026-09-16 quantitative report lowered its price target to $21.00. This is a dated third-party valuation change, not evidence that the market must converge on that price. Argus report summary
• The comparison includes deferred revenue. STAAR’s 2025-11-05 results disclosed that third-quarter 2025 revenue included $25.9 million associated with an earlier China shipment. The next year-over-year comparison therefore requires attention to revenue recognition as well as current orders. Third-quarter 2025 results

Setup & Price Structure

The split- and dividend-adjusted reference close is $20.82 on 2026-09-18. The supplied market series shows a three-month decline of 27.8%, a 52-week high of $33.34 and a distance below that high of 37.6%. The 14-day relative strength index is 41.1. These observations document weakness; they do not establish a reversal.

The $22.00 invalidation and former $23.50 shelf remain historical research levels. The September 18 close establishes that the previously described shelf-underside stabilization did not persist. No moving-average value, trading-volume series, short-interest measure or current ownership filing is available here to substantiate crowding or accumulation.

Company publicity clustered around the September 8 appointment, September 10 report and September 11–15 European Society of Cataract and Refractive Surgeons congress. That establishes corporate communications activity, not retail participation or fund flows. The observations are insufficient to attribute the price decline to those events. Company calendar in report announcement

Catalyst Calendar (next 30 days)

No company-confirmed financial-results event was identified for 2026-09-20 through 2026-10-20 in the reviewed investor calendar. STAAR events calendar

• ~2026-10-07, previously estimated preliminary sales. The September 6 note inferred this window from announcements on 2026-04-08 and 2026-07-16. The sample is too small to support a recurring-schedule claim. A release could provide current demand evidence, but silence on this estimated date would not constitute a missed company commitment.
• ~2026-11-04, previously estimated quarterly results. This later date remains unconfirmed. The next actual results release is the substantive test of distributor conditions and whether ex-China growth improves on the 6.0% reported on 2026-08-12. The estimated date itself supplies no evidence of recovery.

What Would Change Our Mind

The former stabilization case has already lost its defining condition: a weekly close below $22.00 occurred at the September 18 reference close of $20.82. That outcome remains attached to the published thesis.

A replacement recovery case would require both a weekly close above the former $23.50 shelf and the next quarterly disclosure showing ex-China growth above the second quarter’s 6.0%, with distributor inventory still described as within management’s targeted range. Those are explicit conditions for reassessment, not a forecast that they will occur. Any subsequently established recovery case using these conditions would fail on a weekly close below $22.00 or renewed disclosure of excess China distributor inventory.

Correlation Notes

The August 12 geographical sales disclosure identifies China demand as an operating exposure. It does not measure correlation with Chinese equities, currencies or other medical-device stocks. This remains a single-company case: no matched return series or measured peer relationship supports a group-driven recovery claim. The September 18 decline cannot, from the evidence presented, be apportioned between company-specific weakness and broader market movements.